Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress

Reuters

06-11

Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress

Avidity Biosciences, Inc. (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542582460"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542582460\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542582460?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542582460","market":"nz","top_or_hot":-1,"title":"Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences, Inc.</a> (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-11 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences, Inc.</a> (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL2nC696:1","article_id":"2542582460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542582460","pubTimestamp":1749646838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 11, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Avidity Biosciences在FSHD协会大会上公布了Del-brax治疗面肩肱肌营养不良症的1/2期FORTITUDE™试验的主要数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n    \n\nAvidity Biosciences, Inc. (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}